I. Consolidated report

1. Executive summary

Sales in the first nine months 2016 increased by 2.7% in HUF and by 1.6% in EUR terms when compared to the same period 2015. The EURHUF average exchange rate weakened by 1.1% during the first three quarters 2016 compared with the same period of the previous year. Profit from operations decreased by 13.4% in HUF terms (14.3% in EUR terms) as a result of a decline experienced at gross profit level combined with higher sales and marketing expenses, milestone incomes in the reported period falling behind their level reported in the base period, together with certain one-off expenses.

2. Main financial indicators and exchange rates

	HUFm			EURm*		
	2016	2015	Change	2016	2015	Change
	9 months to September		%	9 months to September		%
Total revenues	284,021	276,552	2.7	909.6	895.5	1.6
Gross profit	168,052	169,601	-0.9	538.2	549.2	-2.0
Gross margin %	59.2	61.3		59.2	61.3	
Profit from operations	45,374	52,379	-13.4	145.3	169.6	-14.3
Operating margin %	16.0	18.9		16.0	18.9	
Net financial income / (loss)	2,789	(5,039)	n.a.	8.9	(16.3)	n.a.
Profit before income tax	49,016	48,614	0.8	157.0	157.4	-0.3
Profit attributable to owners of the parent	43,924	44,354	-1.0	140.7	143.6	-2.0
Profit margin attributeable to owners of the parent %	15.5	16.0		15.5	16.0	
EBITDA	71,082	75,871	-6.3	227.6	245.6	-7.3
Basic EPS (HUF, EUR)	237	240	-1.3	0.76	0.78	-2.6
Average exchange rate (EURHUF)*				312.23	308.82	1.1

Note: * Current and historical average exchange rates are shown on page 10.

3. Sales by region

	HUFm				EURm			
	2016	2015	Change		2016	2015	Change	
	9 months to September			%	9 months to September			%
Hungary	27,353	26,762	591	2.2	87.6	86.7	0.9	1.0
EU *	119,732	109,015	10,717	9.8	383.4	353.0	30.4	8.6
Poland	17,420	16,851	569	3.4	55.8	54.6	1.2	2.2
Romania	43,632	36,658	6,974	19.0	139.7	118.7	21.0	17.7
EU 10	17,896	18,107	-211	-1.2	57.3	58.6	-1.3	-2.2
EU 15	40,784	37,399	3,385	9.1	130.6	121.1	9.5	7.8
CIS	88,659	94,845	-6,186	-6.5	284.0	307.1	-23.1	-7.5
Russia	59,227	63,276	-4,049	-6.4	189.7	204.9	-15.2	-7.4
Ukraine	6,373	5,913	460	7.8	20.4	19.1	1.3	6.8
Other CIS	23,059	25,656	-2,597	-10.1	73.9	83.1	-9.2	-11.1
USA	11,281	12,749	-1,468	-11.5	36.1	41.3	-5.2	-12.6
China	18,972	15,940	3,032	19.0	60.8	51.6	9.2	17.8
Latin America	6,929	6,663	266	4.0	22.2	21.6	0.6	2.8
RoW	11,095	10,578	517	4.9	35.5	34.2	1.3	3.8
Total	284,021	276,552	7,469	2.7	909.6	895.5	14.1	1.6

Note: * All Member States of the EU, except for Hungary.

4. Sales report

Sales amounted to HUF 284,021 million (EUR 909.6 million) in the nine months to September 2016, representing a HUF 7,469 million (2.7%) increase. In EUR terms consolidated sales were EUR 14.1 million (1.6%) higher when compared with the first nine months of 2015. A positive performance was recorded in certain markets of the Group.

In **Hungary** sales totalled HUF 27,353 million (EUR 87.6 million) in the first three quarters 2016, a HUF 591 million (EUR 0.9 million) increase compared to the levels reported in the same period 2015.

International sales amounted to EUR 822.0 million in the nine months to September 2016, EUR 13.2 million or 1.6% above the levels recorded in the first three quarters of the previous year. Higher sales performances achieved in Romania, in the EU15 region, in China, in certain markets of the Rest of the World region, in Ukraine, in Poland and in Latin America were partly offset by lower sales levels recorded in Russia, in Other CIS region, in the USA and in the EU10 region. Sales to the CIS region altogether totalled EUR 284.0 million (US$ 317.1 million), EUR 23.1 million (7.5%) or US$ 24.8 million (7.3%) lower when compared to the same period 2015. By the end of the nine months to September 2016 an 18.2% year-on-year devaluation in the average exchange rate of the Rouble against the Euro had occurred in Russia, which was partly offset by an increase in Rouble denominated turnover. In the nine months to September 2016 the Group reported a sales decline of EUR 15.2 million in Russia when compared to the base period. Sales levels reported in RUB terms increased by RUB 1,243.2 million to RUB 14,480.9 million mainly due to certain price increases implemented in February 2016. Following a two year period of severe decline, Ukrainian sales for the first three quarters 2016 reported a slight increase, US$ 1.5 million (EUR 1.3 million), although from a very low base. A EUR 9.2 million (US$ 10.0 million) decline characterised turnover in Other CIS republics as a result of currency devaluations and weak market performance recorded in a number of CIS republics. Turnover of the Wholesaling business segment in the CIS region decreased by EUR 0.7 million in the first three quarters 2016, equivalent to a decline of US$ 0.6 million. The higher turnover of EUR 383.4 million, representing growth of EUR 30.4 million or 8.6%, realised in the EU region resulted primarily from increasing sales levels achieved by the Wholesale and Retail business in Romania, from sales growth reported in the EU15 region and from a good performance of the core segment in both Romania and Poland which altogether more than offset lower turnover experienced in the EU10 region. The Wholesale and Retail business segment in Romania recorded an increase of RON 104.9 million (EUR 22.0 million) when compared to the same period 2015. Sales recorded in the USA decreased by US$ 5.7 million (by EUR 5.2 million) to US$ 40.3 million (EUR 36.1 million) when compared to the same period of the previous year. Royalty income of US$ 3.4 million (EUR 3.1 million) related to first half 2016 sales performance of cariprazine (Vraylar™) contributed to the sales levels achieved in the USA. Turnover reported in China amounted to EUR 60.8 million in the nine months to September 2016. Sales in Latin American countries at US$ 24.8 million in the reported period, were US$ 0.8 million higher when compared to the base period. Sales reported in the Rest of the World region reached EUR 35.5 million in the first three quarters 2016, EUR 1.3 million higher than in the same period of the previous year.

5. Costs, expenses, profits

Cost of sales amounted to HUF 115,969 million (EUR 371.4 million) in the first three quarters 2016, an increase of HUF 9,018 million (EUR 25.1 million) when compared to the same period in 2015. Amortization of the acquired intangible asset Esmya amounted to HUF 2,163 million in the first nine months to September 2016 period.

Gross margin in the first three quarters 2016 at 59.2% declined from the 61.3% level reported for the same period of the previous year. The declining Rouble exchange rate against both the Euro and HUF resulted in falling HUF denominated Russian turnover, while lower sales levels recorded in Other CIS region and in the USA and an increase in the share of turnover of the lower margin wholesale and retail segment in Romania have all negatively impacted gross margin. Higher sales levels recorded in the higher than average margin EU15 region and in China could only partly offset the combination of the negative factors detailed above.

Sales and marketing expenses amounted to HUF 80,305 million (EUR 257.2 million) in the first nine months to September 2016, an increase of 6.1% in HUF terms (4.9% in EUR terms) when compared with the first three quarters 2015. Higher marketing costs incurred on the EU15, on the Chinese and on the Latin American markets were mostly offset by a decrease of such expenses in Russia, in Ukraine and in Other CIS region (notably sales force reductions in the former two countries) together with the devaluation of the Rouble and some of the currencies of Other CIS region countries. The proportion of S&M expenses to sales was 28.3% in the reported period. Amortisation of the marketing and intellectual property rights of the OC portfolio acquired from Grünenthal in the amount of HUF 3,314 million represented 1.2% of sales achieved in the reported period. After adjustment for this amortization, S&M expenses represented 27.1% of turnover. The relevant base period figure was adjusted in accordance with the practice established in the 2015 Annual Report in order to harmonise the presentation of our Latin American subsidiaries with other trading subsidiaries of the Group. Consequently the Administrative and General expenses of these subsidiaries are presented as sales and marketing expenses.

The annual registration fee payable in respect of medical representatives in Hungary amounted to HUF 253 million (EUR 0.8 million) in the first nine months 2016. In accordance with the regulations we expect to offset the tax payable in 2016 on this ground by 90% of the tax liability of the same kind incurred during 2015.

Administrative and general expenses totalled HUF 13,958 million (EUR 44.7 million) in the first nine months 2016, representing a 1.1% increase in HUF terms (remained virtually unchanged in EUR terms) when compared with the level recorded in the first three quarters of the previous year.

Research and development expenses represented 9.3% of sales and decreased by 8.4% in HUF terms (9.4% in EUR terms) to HUF 26,546 million (EUR 85.0 million) during the reported period. These expenses include the ongoing clinical trials being carried out in the field of biotechnology together with those managed in co-operation with Allergan (earlier Forest / Actavis). R&D expenses of the Group also include such costs at the operations of GR Polska and GR Romania.

Other income and other expenses (net) decreased to an expense of HUF 1,869 million (EUR 6.0 million) in the first three quarters 2016 when compared to an income of HUF 1,229 million (EUR 4.0 million) recorded in the base period. This base period figure included an outstanding amount of milestones received from our partners, mainly related to the USA marketing authorization of cariprazine granted by FDA. Similarly Richter accounted in the third quarter 2016 for a one-off income paid by Recordati as an upfront payment, amounting to HUF 3,112 million (EUR 10 million) as stipulated in the concluded agreement relating to future European sales and marketing of cariprazine.

In addition, further one-off income and expense items also impacted results in the reported period. A one-off income amounting to HUF 3,453 million (EUR 11.0 million) was recorded in connection with the 100% acquisition of the joint venture Gedeon Richter Rxmidas JV Co. Ltd. engaged in the trading of OTC products on the Chinese market. Having applied the accounting standards for business combinations as established by IFRS 3 the 50% stake held prior to the transaction was reassessed at fair value at the time of the acquisition (22 January 2016) including the gains proceeding thereof in the Income Statement.

The product withdrawal of Lisvy® (for details please refer to chapter 2.4.3.2 Innovative contraception – Lisvy® on page 27) resulted in a write-off amounting to HUF 2,409 million (EUR 7.7 million) accounted for in respect of intangible assets and HUF 852 million (EUR 2.7 million) in respect of Inventories.

In the nine months to September 2016 an expense of HUF 369 million (EUR 1.2 million) was accounted for in respect of the 20% tax obligation payable with regard to turnover related to reimbursed sales in Hungary. In accordance with the regulations we expect to offset the tax payable in 2016 on this ground by 90% of the tax liability of the same kind incurred during 2015.

During the reported period other income and expenses include liabilities amounting to HUF 4,049 million (EUR 13.1 million) in respect of the claw-back regimes effective in Romania, Germany, France, Spain, Portugal, Belgium, Italy, Bulgaria and Latvia.

Profit from operations decreased by 13.4% in HUF terms (14.3% in EUR terms) and amounted to HUF 45,374 million (EUR 145.3 million) in the first three quarters 2016. The decrease resulted from a decline experienced at gross profit level impacted primarily by the year-on-year 18.2% EURRUB devaluation, by higher sales and marketing expenses and by impairment losses accounted for in respect of Lisvy® product withdrawal, only partly offset by a one-off reassessment-related income, milestone income received from Recordati and lower R&D expenses. The consolidated operating margin decreased to 16.0% during the reported period from the 18.9% reported in the same period 2015. When excluding the impact of the one-off reassessment item in connection with the acquisition of Gedeon Richter Rxmidas JV Co. Ltd., the operating margin was 14.8%

Net financial result for the Group is analysed in detail in the following table:

	HUFm			EURm		
	2016	2015	Change	2016	2015	Change
	9 months to September			9 months to September		
Unrealised financial items	(1,452)	(8,741)	7,289	(4.7)	(28.3)	23.6
Exchange gain/(loss) on trade receivables and trade payables	62	(7,837)	7,899	0.2	(25.4)	25.6
(Loss)/gain on foreign currency loans receivable	(769)	1,157	-1,926	(2.5)	3.8	-6.3
Period end foreign exchange translation difference of borrowings	480	248	232	1.5	0.8	0.7
Exchange loss on other currency related items	(652)	(1,579)	927	(2.1)	(5.1)	3.0
Unwinding of discounted value related to contingent-deferred purchase price liabilities	(571)	(716)	145	(1.8)	(2.3)	0.5
Result of unrealised forward exchange contracts	(2)	(14)	12	0.0	(0.1)	0.1
Realised financial items	4,241	3,702	539	13.6	12.0	1.6
Gain on forward exchange contracts	-	636	-636	-	2.1	-2.1
Exchange gain realised on trade receivables and trade payables	1,481	649	832	4.7	2.1	2.6
Foreign exchange difference on conversion of cash	31	1,061	-1,030	0.1	3.4	-3.3
Dividend income	1,835	1	1,834	5.9	0.0	5.9
Interest income	1,439	2,105	-666	4.6	6.8	-2.2
Interest expense	(603)	(846)	243	(1.9)	(2.7)	0.8
Other financial items	58	96	-38	0.2	0.3	-0.1
Net financial income/(loss)	2,789	(5,039)	7,828	8.9	(16.3)	25.2

The net financial gain in the first three quarters 2016 totalled HUF 2,789 million (EUR 8.9 million), reflecting an increase of HUF 7,828 million (EUR 25.2 million) when compared to a net financial loss of HUF 5,039 million (EUR 16.3 million) recorded in the base period.

At the end of each reporting period foreign currency related assets and liabilities are routinely reassessed with the change in value being reflected as unrealised financial items. The total impact of such reassessments amounted to a HUF 879 million (EUR 2.9 million) loss at 30 September 2016, HUF 7,132 million (EUR 23.0 million) higher when compared with the HUF 8,011 million (EUR 25.9 million) loss reported in the same period of 2015.

A substantial loss accounted for in the base period resulted from exchange translation differences incurred on trade receivables subsequently to the devaluations of Rouble and Kazakh Tenge. Contrary to the above, some exchange gain have been realised on trade receivables during the first nine months 2016.

The net financial gain reported on the realised financial items in the first nine months to September 2016, reflected the impact of exchange gains realised on trade receivables and trade payables amounting to HUF 1,481 million (EUR 4.7 million). This gain incurred primarily as a consequence of the RUBHUF exchange rate which improved in the second part of the reported period when compared to the beginning of 2016. The impact of other key currency exchange rate movements was not significant during the first three quarters 2016. Dividend income contributed HUF 1,835 million (EUR 5.9 million) while net interest income of HUF 836 million (EUR 2.7 million) added to the results achieved.

Share of profit of associates and joint ventures amounted to HUF 853 million (EUR 2.8 million) in the first three quarters 2016.

Profit before income tax amounted to HUF 49,016 million (EUR 157.0 million) in the first nine months to September 2016, an increase of HUF 402 million (a decline of EUR 0.4 million) compared with the same period in 2015.

By virtue of Hungarian Tax Regulations, the **corporate tax** rate applied at the Parent Company of the Group (incorporated in Hungary) can be offset by a tax allowance linked to direct costs incurred on R&D activities. In addition, the Parent Company is also entitled to a tax allowance in respect of the capital expenditure programme carried out at the Debrecen biosimilar manufacturing site. Other members of the Group are subject to customary tax regulations effective in their respective countries of incorporation. During the first nine months to September 2016 the Group accounted for HUF 1,970 million (EUR 6.3 million) in respect of income and deferred tax together with HUF 2,822 million (EUR 9.1 million) local business tax and innovation fee.

Profit for the period was HUF 44,224 million (EUR 141.6 million), marginally higher HUF 94 million (EUR 1.3 million lower) than the profit for the period realised in the first three quarters 2015.

Profit attributable to owners of the parent decreased by HUF 430 million (EUR 2.9 million) during the reported period to HUF 43,924 million (EUR 140.7 million). It decreased to 15.5% of sales compared with the 16.0% reported in the same period of the previous year.

6. Earnings per share

Basic earnings per share totalled HUF 237 per share (EUR 0.76 per share) in the reported period, a decrease of 1.3% (2.6% in EUR terms), when compared to HUF 240 per share (EUR 0.78 per share) recorded in the base period.

Diluted earnings per share totalled HUF 237 per share (EUR 0.76 per share) in the reported period, a decrease of 1.3% (2.6% in EUR terms), when compared to HUF 240 per share (EUR 0.78 per share) recorded in the base period.

The weighted average number of shares in issue used for the EPS calculation on September 30 2016 was 185,593,397 while at the end of the base period it was 184,972,432.

7. Balance sheet

Total assets and total shareholders' equity and liabilities of the Group amounted to HUF 781,097 million on 30 September 2016, HUF 31,903 million, or 4.3% higher than that reported at 31 December 2015.

Non-current assets amounted to HUF 435,747 million on 30 September 2016, nearly the same level as on 31 December 2015. The level of Other intangible assets decreased as result of the impairment losses accounted for in respect of the product withdrawal of Lisvy® together with the amortization and the foreign exchange difference at period-end related to the Esmya intangible asset. The above was partly offset by an increase in the level of the Goodwill resulting from the reassessment made in respect of the Chinese acquisition together with the revaluation of the Goodwill accounted for in respect of the acquisitions realised in the preceding years. As the allocation of the purchase price of the Chinese acquisition has not been completed by the publication date of this interim report the Company has included unallocated amounts in the Goodwill presented. Furthermore, the level of Other financial assets increased as a result of a change in the fair value of Richter's investment in its Russian wholesaler and retail Group, Protek together with the change in the level of Property, plant and equipment.

Current assets amounted to HUF 345,350 million and increased by HUF 31,950 million (10.2%) when compared to the level reported on 31 December 2015. The acquisition of Finox Holding was completed at the time of the financial settlement of the transacttion (CHF 190 million) while the companies belonging to the holding organisation are currently being included in the consolidation resulting in an increase reported in the level of Other current assets and a decrease in the amount of Cash and cash equivalents with the latter being also negatively impacted by a loan repayment amounting to EUR 17 million.

Capital and reserves of the Group increased by 5.4% and amounted to HUF 653,918 million when compared to the balance as at 31 December 2015. Retained earnings increased by HUF 30,562 million and amounted to HUF 593,584 million.

Non-current liabilities of the Group on 30 September 2016 at HUF 42,473 million were HUF 14,399 million lower than the levels as at the end of the previous year. The decline is a result of reclassification as current liabilities, i.e. with payments due within a year of an EUR 21 million loan together with deferred purchase price payments related to our acquisitions in China and in Mexico.

Current liabilities of the Group at HUF 84,706 million on 30 September 2016 were HUF 12,973 million higher than their level reported on 31 December 2015. The increase was a result of a decline in Trade payables having been more than offset by higher Other payables and accruals during the reported period.

8. Capital expenditure

Capital expenditure for the Group including payments for intangible assets totalled HUF 20,347 million in the nine months to September 2016 when compared to HUF 19,239 million reported for the same period 2015.

9. Corporate matters

9.1 Information regarding Richter shares

9.1.1 The number of shares in issue at 30 September 2016 was unchanged compared to 30 September 2016, i.e. 186,374,860 shares.

9.1.2 The number of shares held by the Parent company in Treasury increased slightly during the third quarter of 2016.

	Ordinary shares				
	30 September 2016	30 June 2016	31 March 2016	31 December 2015	30 September 2015
Number	90,988	87,588	108,353	101,371	178,885
Book value (HUF '000)	492,763	473,358	587,217	549,820	751,791

On 30 September 2016 the Group's subsidiaries held a total of 660,284 ordinary Richter shares.

In accordance with a repurchase obligation related to employee share bonuses, the Company repurchased 3,400 shares from employees who resigned from the Parent company during the third quarter 2016.

The Board of Directors of Gedeon Richter Plc. first decided to introduce a bonus share programme at the Company in 1996. Beneficiaries of the programme are the heads of departments, senior managers and selected key employees of the Company. Based on a detailed assessment of the individual's performance, bonus shares are granted at the end of every six months. Bonus shares to be granted at the end of the second half of 2016 are expected to amount to HUF 461 million.

The total number of Company shares at Group level held in Treasury at 30 September 2016 was 751,272.

9.2 Share ownership structure

The shareholder structure at 30 September 2016 is presented in detail in the following table:

Ownership	Ordinary shares Number	Voting rights %	Share capital %
Domestic ownership	59,593,128	32.11	31.97
State ownership total	47,051,817	25.35	25.25
out of which MNV Zrt.	47,051,668	25.35	25.25
out of which Municipality	149	0.00	0.00
Institutional investors	6,103,261	3.29	3.27
Retail investors	6,438,050	3.47	3.45
International ownership	125,996,044	67.87	67.61
Institutional investors	125,124,773	67.40	67.14
out of which Aberdeen Asset Mgmt. Plc.	18,243,530	9.83	9.79
Retail investors	871,271	0.47	0.47
Treasury shares*	751,272	0.00	0.40
Undisclosed ownership	34,416	0.02	0.02
Share capital	186,374,860	100.00	100.00

Note: * Treasury shares include the combined ownership of the parent company and subsidiaries.

Data in the above table were compiled based on the share registry amended with information provided by KELER Zrt. as clearing company, global custodians and nominees. Due to the confidential character of linked investor interests certain investment funds may keep a different record of their respective share capital and/or voting rights.

9.3 Extraordinary announcements

9.3.1 The Company announced by the means of extraordinary announcement both the acquisition of Finox Holding (30 June 2016) and the closing of the transaction (8 July 2016). At the closing of the transaction the company assumed control and commenced the integration of the companies belonging to Finox Holding into Richter Group. This procedure involves the complete incorporation in the consolidated financial statements of the Richter Group of the assets and liabilities acquired together with the proceedings and expenses incurred subsequent to the transaction. The integration of Finox Group will be completed by the time of publication of the quarterly report for 12 months to December 2016.

9.3.2 On 2 August 2016 Gedeon Richter Plc. and Recordati announced the signing of an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic in Western Europe, in Algeria, in Tunisia and in Turkey.

9.3.3 On 5 August 2016 Gedeon Richter Plc. and Allergan plc provided an update on certain trials and regulatory issues related to ongoing cariprazine development. The joint release included information on the topline results of the MD-72 flexible doses trial of cariprazine which did not show significant difference compared to placebo used in adjunctive treatment to antidepressant therapy in adults with major depressive disorder (MDD) treatment.

9.3.4 On 6 September 2016 Gedeon Richter Plc. informed its shareholders that with effect from 5 September 2016, Mr Gábor Orbán was appointed as the Company's Director of Corporate Strategy. Mr Orbán was also appointed to the Company's Executive Board.

9.3.5 On 19 October 2016 Gedeon Richter Plc. announced that it had signed a technology transfer and license-in agreement with DM Bio in respect of the development and commercialization of DM Bio's biosimilar monoclonal antibody, Trastuzumab. (DM Bio is a joint venture company formed by Dong-A Socio Holdings of Korea and Meiji Seika Pharma of Japan.)

10. Historical exchange rates

10.1 At period end

	30.09.2016	30.06.2016	31.03.2016	31.12.2015	30.09.2015
EURHUF	309.15	316.16	314.16	313.12	313.32
US$HUF	276.35	284.29	276.62	286.63	279.05
RUBHUF	4.36	4.43	4.09	3.88	4.26
EURRUB	70.91	71.37	76.81	80.70	73.55
EURUS$	1.12	1.11	1.14	1.09	1.12

10.2 Average

	2016 M9	2016 H1	2016 Q1	2015 M12	2015 M9
EURHUF	312.23	312.67	311.98	309.67	308.82
US$HUF	279.64	279.95	283.12	279.16	277.39
RUBHUF	4.09	4.00	3.77	4.70	4.78
EURRUB	76.34	78.17	82.75	65.89	64.61
EURUS$	1.12	1.12	1.10	1.11	1.11

Company name: Gedeon Richter Plc.
Company address: 1103 Budapest, Gyömrői út 19-21., Hungary
Sector: Pharmaceutical
Reporting period: January-September 2016

Telephone: +36-1-431-5764
Fax: +36-1-261-2158
E-mail address: investor.relations@richter.hu
Investor relations manager: Katalin Ördög

Balance Sheet

	30 September 2016 Unaudited HUFm	31 December 2015 Audited HUFm	Change %
ASSETS	781,097	749,194	4.3
Non-current assets	435,747	435,794	0.0
Property, plant and equipment	179,697	175,355	2.5
Goodwill	69,200	64,888	6.6
Other intangible assets	139,043	150,827	-7.8
Investments in associates and joint ventures	7,585	7,140	6.2
Other financial assets	29,844	26,414	13.0
Deferred tax assets	5,904	7,487	-21.1
Loans receivable	4,474	3,683	21.5
Current assets	345,350	313,400	10.2
Inventories	80,236	70,051	14.5
Trade receivables	109,661	92,539	18.5
Other current assets	70,267	13,927	404.5
Investments in securities	19	3,970	-99.5
Current tax assets	117	539	-78.3
Cash and cash equivalents	85,050	132,374	-35.8
EQUITY AND LIABILITIES	781,097	749,194	4.3
Capital and reserves	653,918	620,589	5.4
Share capital	18,638	18,638	0.0
Treasury shares	(2,943)	(3,206)	-8.2
Share premium	15,214	15,214	0.0
Capital reserves	3,475	3,475	0.0
Foreign currency translation reserves	15,018	16,478	-8.9
Revaluation reserve for available for sale investments	7,213	3,323	117.1
Retained earnings	593,584	563,022	5.4
Non-controlling interest	3,719	3,645	2.0
Non-current liabilities	42,473	56,872	-25.3
Borrowings	30,091	37,188	-19.1
Deferred tax liability	8,479	8,939	-5.1
Other non-current liabilities and accruals	1,050	7,817	-86.6
Provisions	2,853	2,928	-2.6
Current liabilities	84,706	71,733	18.1
Borrowings	7,729	6,523	18.5
Trade payables	33,294	38,209	-12.9
Current tax liabilities	419	425	-1.4
Other current liabilities and accruals	41,412	24,669	67.9
Provisions	1,852	1,907	-2.9

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.
Company address: 1103 Budapest, Gyömrői út 19-21., Hungary
Sector: Pharmaceutical
Reporting period: January-September 2016

Telephone: +36-1-431-5764
Fax: +36-1-261-2158
E-mail address: investor.relations@richter.hu
Investor relations manager: Katalin Ördög

Consolidated statement of changes in equity

HUFm	Share capital	Share premium	Capital reserves	Treasury shares	Foreign currency translation reserves	Retained earnings	Revaluation reserve for available for sale investments	Attributable to owners of the parent	Non-controlling interest	Total
Balance at 31 December 2015	18,638	15,214	3,475	(3,206)	16,478	563,022	3,323	**616,944**	3,645	**620,589**
Profit for the period	-	-	-	-	-	43,924	-	**43,924**	300	**44,224**
Exchange differences arising on translation of foreign operations	-	-	-	-	(1,693)	-	-	**(1,693)**	(87)	**(1,780)**
Exchange differences arising on translation of associates and joint ventures	-	-	-	-	233	-	-	**233**	-	**233**
Revaluation for available for sale investments	-	-	-	-	-	-	3,890	**3,890**	-	**3,890**
Comprehensive income at 30 September 2016	-	-	-	-	(1,460)	43,924	3,890	**46,354**	213	**46,567**
Net treasury shares transferred and purchased	-	-	-	263	-	-	-	**263**	-	**263**
Ordinary share dividend for 2015	-	-	-	-	-	(13,419)	-	**(13,419)**	-	**(13,419)**
Dividend paid to non-controlling interest	-	-	-	-	-	-	-	**-**	(139)	**(139)**
Recognition of share-based payments	-	-	-	-	-	57	-	**57**	-	**57**
Balance at 30 September 2016	18,638	15,214	3,475	(2,943)	15,018	593,584	7,213	**650,199**	3,719	**653,918**

Company name: Gedeon Richter Plc.
Company address: 1103 Budapest, Gyömrői út 19-21., Hungary
Sector: Pharmaceutical
Reporting period: January-September 2016

Telephone: +36-1-431-5764
Fax: +36-1-261-2158
E-mail address: investor.relations@richter.hu
Investor relations manager: Katalin Ördög

Income Statement

For the year ended 31 December 2015 Audited HUFm		For the period ended 30 September 2016 Unaudited HUFm	2015 Unaudited* HUFm	Change %
365,220	Total revenues	284,021	276,552	2.7
(143,761)	Cost of sales	(115,969)	(106,951)	8.4
221,459	Gross profit	168,052	169,601	-0.9
(98,310)	Sales and marketing expenses	(80,305)	(75,679)	6.1
(19,397)	Administration and general expenses	(13,958)	(13,805)	1.1
(34,822)	Research and development expenses	(26,546)	(28,967)	-8.4
(1,398)	Other income and other expenses (net)	(1,869)	1,229	n.a.
67,532	Profit from operations	45,374	52,379	-13.4
24,230	Finance income	15,899	20,495	-22.4
(32,537)	Finance cost	(13,110)	(25,534)	-48.7
(8,307)	Net financial income/(loss)	2,789	(5,039)	n.a.
1,502	Share of profit of associates and joint ventures	853	1,274	-33.0
60,727	Profit before income tax	49,016	48,614	0.8
(2,332)	Income and deferred tax	(1,970)	(1,602)	23.0
(3,850)	Local business tax and innovation contribution	(2,822)	(2,882)	-2.1
54,545	Profit for the period	44,224	44,130	0.2
	Profit attributable to:			
54,277	Owners of the parent	43,924	44,354	-1.0
268	Non-controlling interest	300	(224)	n.a.
	Statement of comprehensive income			
54,545	Profit for the period	44,224	44,130	0.2
(22)	Actuarial loss on retirement defined benefit plans	-	-	n.a.
(22)	Items that will not be reclassified to profit or loss	-	-	n.a.
7,179	Exchange differences arising on translation of foreign operations	(1,780)	8,418	n.a.
51	Exchange differences arising on translation of associates and joint ventures	233	46	406.5
1,447	Revaluation for available for sale investments	3,890	301	n.a.
8,677	Items that may be subsequently reclassified to profit or loss	2,343	8,765	-73.3
8,655	Other comprehensive income	2,343	8,765	-73.3
63,200	Total comprehensive income	46,567	52,895	-12.0
	Attributable to:			
62,818	Owners of the parent	46,354	53,038	-12.6
382	Non-controlling interest	213	(143)	n.a.
HUF	**Earnings per share (EPS)**	**HUF**	**HUF**	**%**
292	Basic	237	240	-1.3
292	Diluted	237	240	-1.3

Note: * The relevant base period figure was adjusted in accordance with the practice established in the 2015 Annual Report in order to harmonise the presentation of our Latin American subsidiaries with other trading subsidiaries of the Group. Consequently the Administrative and General expenses of these subsidiaries are presented as Sales and marketing expenses.

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.
Company address: 1103 Budapest, Gyömrői út 19-21., Hungary
Sector: Pharmaceutical
Reporting period: January-September 2016

Telephone: +36-1-431-5764
Fax: +36-1-261-2158
E-mail address: investor.relations@richter.hu
Investor relations manager: Katalin Ördög

Income Statement

For the year ended 31 December 2015 Audited EURm		For the period ended 30 September 2016 Unaudited EURm	2015 Unaudited* EURm	Change %
1,179.4	Total revenues	909.6	895.5	1.6
(464.3)	Cost of sales	(371.4)	(346.3)	7.2
715.1	Gross profit	538.2	549.2	-2.0
(317.5)	Sales and marketing expenses	(257.2)	(245.1)	4.9
(62.6)	Administration and general expenses	(44.7)	(44.7)	0.0
(112.4)	Research and development expenses	(85.0)	(93.8)	-9.4
(4.5)	Other income and other expenses (net)	(6.0)	4.0	n.a.
218.1	Profit from operations	145.3	169.6	-14.3
78.3	Finance income	50.9	66.4	-23.3
(105.1)	Finance cost	(42.0)	(82.7)	-49.2
(26.8)	Net financial income/(loss)	8.9	(16.3)	n.a.
4.8	Share of profit of associates and joint ventures	2.8	4.1	-31.7
196.1	Profit before income tax	157.0	157.4	-0.3
(7.6)	Income and deferred tax	(6.3)	(5.2)	21.2
(12.4)	Local business tax and innovation contribution	(9.1)	(9.3)	-2.2
176.1	Profit for the period	141.6	142.9	-0.9
	Profit attributable to:			
175.3	Owners of the parent	140.7	143.6	-2.0
0.8	Non-controlling interest	0.9	(0.7)	n.a.
309.67	Average exchange rate (EURHUF)	312.23	308.82	1.1
	Statement of comprehensive income			
176.1	Profit for the period	141.6	142.9	-0.9
(0.1)	Actuarial loss on retirement defined benefit plans	-	-	n.a.
(0.1)	Items that will not be reclassified to profit or loss	-	-	n.a.
23.2	Exchange differences arising on translation of foreign operations	(5.7)	27.3	n.a.
0.2	Exchange differences arising on translation of associates and joint ventures	0.7	0.1	600.0
4.7	Revaluation for available for sale investments	12.5	1.0	n.a.
28.1	Items that may be subsequently reclassified to profit or loss	7.5	28.4	-73.6
28.0	Other comprehensive income	7.5	28.4	-73.6
204.1	Total comprehensive income	149.1	171.3	-13.0
	Attributable to:			
202.9	Owners of the parent	148.5	171.7	-13,5
1.2	Non-controlling interest	0.6	(0.4)	n.a.
EUR	**Earnings per share (EPS)**	**EUR**	**EUR**	**%**
0.94	Basic	0.76	0.78	-2.6
0.94	Diluted	0.76	0.78	-2.6

Note: * The relevant base period figure was adjusted in accordance with the practice established in the 2015 Annual Report in order to harmonise the presentation of our Latin American subsidiaries with other trading subsidiaries of the Group. Consequently the Administrative and General expenses of these subsidiaries are presented as Sales and marketing expenses.
Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.
Company address: 1103 Budapest, Gyömrői út 19-21., Hungary
Sector: Pharmaceutical
Reporting period: January-September 2016

Telephone: +36-1-431-5764
Fax: +36-1-261-2158
E-mail address: investor.relations@richter.hu
Investor relations manager: Katalin Ördög

Income Statement

	July-September 3 months					
	2016	2015*	Change	2016	2015*	Change
	HUFm	HUFm	%	EURm	EURm	%
Total revenues	96,749	92,599	4.5	310.7	296.4	4.8
Cost of sales	(40,366)	(39,668)	1.8	(129.6)	(127.2)	1.9
Gross profit	56,383	52,931	6.5	181.1	169.2	7.0
Sales and marketing expenses	(25,922)	(24,301)	6.7	(83.3)	(77.8)	7.1
Administration and general expenses	(4,642)	(4,569)	1.6	(14.9)	(14.6)	2.1
Research and development expenses	(6,789)	(7,976)	-14.9	(21.8)	(25.4)	-14.2
Other income and other expenses (net)	(1,657)	4,645	n.a.	(5.4)	15.1	n.a.
Profit from operations	17,373	20,730	-16.2	55.7	66.5	-16.2
Finance income	2,583	(5,012)	n.a.	8.3	(16.7)	n.a.
Finance cost	(4,330)	(7,947)	-45.5	(13.9)	(25.4)	-45.3
Net financial loss	(1,747)	(12,959)	-86.5	(5.6)	(42.1)	-86.7
Share of (loss)/profit of associates and joint ventures	(143)	267	n.a.	(0.3)	0.8	n.a.
Profit before income tax	15,483	8,038	92.6	49.8	25.2	97.6
Income and deferred tax	(693)	(163)	325.2	(2.2)	(0.5)	340.0
Local business tax and innovation contribution	(939)	(1,126)	-16.6	(3.1)	(3.6)	-13.9
Profit for the period	13,851	6,749	105.2	44.5	21.1	110.9
Profit attributable to:						
Owners of the parent	13,629	6,846	99.1	43.8	21.4	104.7
Non-controlling interest	222	(97)	n.a.	0.7	(0.3)	n.a.
Average exchange rate (EURHUF)				311.26	319.86	-2.7

Earnings per share (EPS)	HUF	HUF	%	EUR	EUR	%
Basic	74	37	100.0	0.24	0.12	100.0
Diluted	74	37	100.0	0.24	0.12	100.0

Note: * The relevant base period figure was adjusted in accordance with the practice established in the 2015 Annual Report in order to harmonise the presentation of our Latin American subsidiaries with other trading subsidiaries of the Group. Consequently the Administrative and General expenses of these subsidiaries are presented as Sales and marketing expenses.

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.
Company address: 1103 Budapest, Gyömrői út 19-21., Hungary
Sector: Pharmaceutical
Reporting period: January-September 2016

Telephone: +36-1-431-5764
Fax: +36-1-261-2158
E-mail address: investor.relations@richter.hu
Investor relations manager: Katalin Ördög

Cash flow Statement

For the year ended 31 December 2015 Audited HUFm		For the period ended 30 September 2016 Unaudited HUFm	2015 Unaudited HUFm
	Operating activities		
54,277	Profit attributable to owners of the parent	43,924	44,354
31,227	Depreciation and amortisation	23,873	23,491
(1,582)	Non cash items accounted through Total Comprehensive Income	(3,513)	(1,200)
(243)	Period end foreign exchange translation difference of borrowings	(480)	(248)
(1,482)	Net interest and dividend income	(2,671)	(1,260)
6,182	Income tax recognised through Income Statement	4,792	4,484
158	Changes in provision for defined benefit plans	(53)	-
(830)	(Increase)/decrease on changes of property, plant and equipment and intangible assets	(55)	1,460
3,484	Impairment recognised on intangible assets	3,523	3,144
4,260	Expense recognised in respect of equity-settled share-based payments	340	-
	Movements in working capital		
2,773	Increase in trade and other receivables	(14,380)	(9,637)
(3,599)	Increase in inventories	(11,439)	(4,446)
7,231	Increase in trade payables and other current and non-current liabilities	11,651	14,861
(1,160)	Interest expense	(603)	(846)
(5,649)	Income tax paid	(3,437)	(3,782)
95,047	Net cash flow from operating activities	51,472	70,375
	Investing activities		
(27,708)	Payments for property, plant and equipment	(18,709)	(14,898)
(5,594)	Payments for intangible assets	(1,638)	(4,341)
1,332	Proceeds from disposal of property, plant and equipment	325	1,119
(2,043)	Payments to acquire financial assets	(94)	(1,537)
18,429	Proceeds on sale or redemption on maturity of financial assets	3,951	10
(836)	Disbursement of loans	(681)	(1,118)
2,641	Interest income	1,439	2,105
1	Dividend income	1,835	1
(25,322)	Net cash outflow on acquisition of subsidiaries	(66,821)	(24,367)
(39,100)	Net cash flow to investing activities	(80,393)	(43,026)
	Financing activities		
(2,542)	Purchase of treasury shares	(77)	(276)
(6,155)	Dividend paid	(13,414)	(6,155)
(14,628)	Repayment of borrowings (-)	(5,403)	(7,925)
2	Proceeds from borrowings (+)	-	-
(23,323)	Net cash flow to financing activities	(18,894)	(14,356)
32,624	Net (decrease)/increase in cash and cash equivalents	(47,815)	12,993
97,940	Cash and cash equivalents at beginning of year	132,374	97,940
1,810	Effect of foreign exchange rate changes on the balances held in foreign currencies	491	1,625
132,374	Cash and cash equivalents at end of period	85,050	112,558

Prepared in accordance with IAS 34 Interim Financial Reporting.

I. Report by business segment

1. Business segment information

The activities of Richter Group are presented in this Report along three operating segments. Those subsidiaries of the Group that are engaged in the core activities of research and development together with manufacturing and sale of pharmaceutical products have been classified as the Pharmaceutical segment. The performance of those distributor and retail subsidiaries that represent the distribution chain in some of our markets and facilitate our products reaching final buyers are presented under the Wholesale and Retail segment. Finally, the Other segment relates to the business of those group members that do not belong to any of the above segments. These companies provide services to group members belonging to the Pharmaceutical segment.

In the following section we present key data by business segments.

HUFm	Pharmaceuticals		Wholesale and retail		Other		Eliminations		Group total	
	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015
	9 months to September		9 months to September		9 months to September		9 months to September		9 months to September	
Total revenues	237,277	236,378	53,308	46,104	3,345	3,257	(9,909)	(9,187)	284,021	276,552
Gross profit	162,091	163,753	5,395	5,897	458	394	108	(443)	168,052	169,601
Profit from operations	45,231	52,295	519	609	126	(116)	(502)	(409)	45,374	52,379
Share of profit of associates and joint ventures	(772)	222	1,713	1,290	19	(30)	(107)	(208)	853	1,274
Number of employees at period end	9,975	9,629	1,458	1,449	351	343	-	-	11,784	11,421

2. Pharmaceuticals sales report

Sales in the pharmaceutical segment in the first three quarters 2016 totalled HUF 237,277 million (EUR 759.9 million), representing a virtually flat performance both in HUF terms and in EUR terms (an increase of 0.4% in HUF terms and a decrease of 0.7% in EUR terms) compared to the same period of last year.

2.1 Pharmaceutical sales by region in currencies of invoicing

As a result of extraordinary movements experienced in the recent past in the exchange rate of certain currencies with a major impact on our key markets it has been decided to present sales dynamics achieved on each of our reporting regions/markets in the respective currencies of invoicing. For those regions in which Richter operates with multiple currencies turnover figures have been provided in the most important currencies.

	Currency (million units)	2016	2015	Change %
		9 months to September		
Hungary	HUF	26,753	26,151	2.3
EU *	EUR	266.2	255.3	4.3
Poland	PLN	243.5	226.7	7.4
Romania	RON	100.7	93.3	8.0
EU 10	EUR	57.3	58.6	-2.2
EU 15	EUR	130.6	121.0	7.9
CIS	EUR	261.4	283.8	-7.9
	US$	291.9	315.9	-7.6
Russia	RUB	14,480.3	13,236.7	9.4
Ukraine	US$	22.7	21.1	7.6
Other CIS	EUR	51.4	59.9	-14.2
	US$	57.4	66.7	-13.9
USA	US$	40.3	46.0	-12.4
China	EUR	60.8	51.6	17.8
Latin America	US$	16.0	16.1	-0.6
RoW	EUR	35.5	34.2	3.8
	US$	39.6	38.1	3.9

Note: * All Member States of the EU, except for Hungary.

2.2 Pharmaceutical sales by region

	HUFm				EURm			
	2016	2015	Change		2016	2015	Change	
	9 months to September			%	9 months to September			%
Hungary	26,753	26,151	602	2.3	85.6	84.7	0.9	1.1
EU *	83,101	78,839	4,262	5.4	266.2	255.3	10.9	4.3
Poland	17,420	16,851	569	3.4	55.8	54.6	1.2	2.2
Romania	7,010	6,500	510	7.8	22.5	21.1	1.4	6.6
EU 10	17,896	18,107	-211	-1.2	57.3	58.6	-1.3	-2.2
EU 15	40,775	37,381	3,394	9.1	130.6	121.0	9.6	7.9
CIS	81,618	87,645	-6,027	-6.9	261.4	283.8	-22.4	-7.9
Russia	59,224	63,272	-4,048	-6.4	189.7	204.9	-15.2	-7.4
Ukraine	6,335	5,869	466	7.9	20.3	19.0	1.3	6.8
Other CIS	16,059	18,504	-2,445	-13.2	51.4	59.9	-8.5	-14.2
USA	11,281	12,749	-1,468	-11.5	36.1	41.3	-5.2	-12.6
China	18,972	15,940	3,032	19.0	60.8	51.6	9.2	17.8
Latin America	4,468	4,476	-8	-0.2	14.3	14.5	-0.2	-1.4
RoW	11,084	10,578	506	4.8	35.5	34.2	1.3	3.8
Total	237,277	236,378	899	0.4	759.9	765.4	-5.5	-0.7
Average exchange rate (EURHUF)					312.23	308.82	3.41	1.1

Note: * All Member States of the EU, except for Hungary.

A list of products referred to in this report is presented in Appendix 1 on page 31.

2.2.1 Hungary

In **Hungary** sales totalled HUF 26,753 million (EUR 85.6 million) in the first three quarters 2016, a slight increase of 2.3% in HUF terms (1.1% in EUR terms) compared with the same period in 2015. A number of products showed significant sales growth during the reported period, notably Suprax, Esmya®, Vidotin Komb and Duamild.

Marginal changes to the price regulation system did not impact materially the Group's overall performance in the reported period. However, a tender system first introduced in 2011 aiming towards semestral price adjustments adversely affected several major Richter brands in Hungary. Price cuts applied with effect from 1 October 2016 are expected to amount to an annual revenue loss of approximately HUF 39 million.

Based on the latest available market audit (IMS) data for the nine months to September 2016 the pharmaceutical market increased by 4.5% year-on-year. Retail sales of Richter products increased by 6.7% compared to the same period 2015 and the Company is now the third player on the Hungarian pharmaceutical market with a 5.4% share. When considering only the market for retail prescription drugs, Richter qualifies for second place with a market share of 7.3%.

2.2.2 Hungarian regulatory environment

The Hungarian market has stabilised, albeit at significantly lower levels than a few years ago. Extraordinary taxes levied on the industry are reclaimable at a maximum rate of 90% subject to adequate R&D expenditures and employment levels being maintained. Given its high level of such expenses Richter qualifies for this maximum allowance. Furthermore by virtue of the law, the R&D linked allowances may be carried over across calendar years.

The methodology for the tax calculations related to healthcare budget overspending was amended with effect from 1 January 2016 which may lead to additional tax becoming payable in the case of potential overspending.

2.2.3 European Union

Sales in the **European Union**, excluding Hungary, amounted to EUR 266.2 million in the first nine months of 2016, 4.3% higher than the levels recorded in the same period of 2015.

In **Poland** the Group recorded sales of PLN 243.5 million (EUR 55.8 million) in the first three quarters of 2016, an increase of 7.4% in PLN terms (2.2% in EUR terms) compared to the same period of 2015. Due to a strong flu season, sales of our leading product, Groprinosin substantially increased during the reported period. Furthermore a number of products recorded good sales growth during the reported period, notably Grofibrat (Grofibrat S), Mydocalm and Cavinton. Nevertheless, sales continued to be adversely impacted by price erosion on some of our generic products and parallel imports of certain other products.

In **Romania** sales amounted to RON 100.7 million (EUR 22.5 million) in the first three quarters of 2016, an increase of 8.0% in RON terms (6.6% in EUR terms) when compared to the base period. Wholesalers, in expectation of an announced price decrease had maintained low stock levels during the first half 2015. Sales of Cavinton, Lunaldin, Fasconal and Kalmopyrin contributed the most to the sales growth achieved during the reported period.

In the **EU10** region sales totalled EUR 57.3 million in the first nine months of 2016, 2.2% lower when compared to base period. This region represented 22% of total EU sales of the Group's pharmaceutical segment.

In the **Czech Republic** turnover in the nine months to September 2016 amounted to CZK 463.4 million (EUR 17.1 million), a decline of 4.7% in CZK terms (3.6% in EUR terms) compared to the sales level achieved in the base period. Turnover of the range of oral contraceptives, Verospiron, Lunaldin and Mertenil were the major contributors to the sales levels achieved in the reported period. In **Slovakia** turnover amounted to EUR 14.7 million in the first three quarters 2016, 5.3% higher compared to the same period in 2015. Sales growth of Esmya®, Aflamil, Ossica and Vidonorm contributed the most to the higher turnover achieved during the reported period. In the **Baltic States** sales amounted to EUR 10.0 million in the first three quarters 2016, EUR 2.0 million lower when compared to the same period 2015. The substantial year-on-year decline was primarily due to the termination in March 2015 of the licensing agreement for Avonex and a change implemented in our distribution channel in these countries with effect from 1 January 2016. In **Bulgaria** sales totalled EUR 12.4 million in the reported period, representing a virtually flat performance (EUR 0.1 million lower) when compared with turnover achieved in the base period.

In the **EU15** region sales amounted to EUR 130.6 million in the first nine months to September 2016, 7.9% higher in EUR terms than in the corresponding period of the previous year. This region contributed 49% of total EU pharmaceutical sales.

In **Germany,** the largest market for the Group in the region, the reported sales of EUR 44.5 million in the first three quarters of 2016 was 5.7% lower when compared to the base period. According to IMS market intelligence the overall OC market has also declined in Germany. Turnover in **Spain** totalled EUR 15.6 million in the first nine months 2016, exceeding the base period by EUR 4.8 million, mainly due to higher Esmya® sales. In **Italy** the Group's turnover amounted to EUR 15.5 million, 14.0% higher than in the base period. Sales in **France** amounted to EUR 15.4 million in the first nine months of 2016, representing a 4.2% decline compared with the same period in 2015. Sales in the **UK** were EUR 14.5 million in the reported period, an increase of 9.3% when compared to the same period 2015 mainly attributable to good Esmya® sales. Turnover in the **Benelux countries** were EUR 10.0 million, while sales in **Portugal** amounted to EUR 8.4 million, EUR 2.9 million higher than in the base period, mainly due to good sales performance of the range of oral contraceptives and Esmya®.

2.2.4 CIS

Sales to the **CIS** in the first nine months to September 2016 totalled EUR 261.4 million, a decline of EUR 22.4 million (7.9%) compared to the sales levels achieved in the same period 2015. Lower sales in Other CIS republics and the EUR denominated sales reduction incurred in Russia as a result of the adverse FX environment impacted primarily on sales performance achieved in this region.

According to the latest available market intelligence **Russia**'s real GDP contracted by 0.6% year-on-year by the end of the first half 2016. Following a depreciation of the Rouble against the Euro prevailing until mid February and peaking at EURRUB 90, the Russian currency strengthened to just above EURRUB 70 by the end of September 2016. Although the third quarter ended with falling oil prices, news of possible OPEC production cuts resulted in an easing of the inflation rate to 6.4% by the end of September 2016 and a further strengthening Rouble at the beginning of the fourth quarter. The World Bank's latest, October report on Russia noted that weak income dynamics could not support consumer demand in August and retail trade contracted by 5.1% by the end of August 2016.

Sales to Russia totalled RUB 14,480.3 million in the first nine months to September 2016 period, RUB 1,243.6 million higher when compared to the same period in 2015. The higher turnover achieved resulted from both a price increase which was applied during the first quarter 2016 to certain products of our portfolio (which, when projected across the entire range of products, resulted in an average 4% price increase) and growing volumes. During the first three quarters 2016 the year-on-year devaluation (18.2%) of the average exchange rate of the Rouble against the Euro impacted negatively our performance in Russia. Sales levels during the reported period at EUR 189.7 million were EUR 15.2 million below the turnover reported in the same period 2015. Good sales performances of Mydocalm, the range of oral contraceptives, Verospiron, Groprinosin and Airtal contributed the most to higher RUB turnover achieved in Russia.

Sales to **Ukraine** amounted to US$ 22.7 million (EUR 20.3 million) in the first three quarters 2016, an increase of US$ 1.6 million (EUR 1.3 million) compared to the turnover reported for the same period 2015, although from a very low base. A more strict receivables control and voluntary shipment restrictions were implemented by the Company as a reaction to the political turmoil and the deep economic recession which have characterised the country since the beginning of 2014. By the end of the reported period, the local currency, UAH, had devalued against the US$ by 18.6% year-on-year.

Sales in **Other CIS republics** totalled EUR 51.4 million (US$ 57.4 million) in the first nine months to September 2016, representing a decrease of EUR 8.5 million (US$ 9.3 million) compared to the same period in 2015. Oil and natural gas prices have been falling over the past two years which combined with currency devaluations in most of the countries have negatively impacted the overall performance of this region. Nothwithstanding this economic background, sales growth was achieved when reported in Euro terms in **Moldavia** and in **Tajikistan,** although from a low base. In mid August 2015 the Kazakh Tenge (KZT) was floated which resulted in a more volatile FOREX environment. Sales declines, resulting from deteriorating exchange rates and weaker market performance, prevailed in most of the countries of the region, primarily in **Belarus** and in **Kazakhstan** with the latter experiencing a sharply declining (by 72.6%) EURKZT average exchange rate by the end of the first nine months of 2016 when compared with the base period.

2.2.5 USA

Sales in the **USA** totalled US$ 40.3 million (EUR 36.1 million) in the first nine months of 2016, a decrease of 12.4% in US$ terms (12.6% in EUR terms). Revenues resulting from the oral contraceptive related profit sharing agreements declined substantially due to increased generic competition while proceeds from our emergency contraceptives further increased during the reported period.

Royalty income of US$ 3.4 million (EUR 3.1 million) related to the first half 2016 sales performance of cariprazine (Vraylar™) contributed to the sales levels achieved during the reported period.

2.2.6 China

Sales to **China** amounted to EUR 60.8 million in the first nine months of 2016, 17.8% higher than in the base period. Turnover of Cavinton and Escapelle contributed the most to the sales growth recorded.

2.2.7 Latin America

Sales in Latin American countries amounted to US$ 16.0 million in the first three quarters 2016, representing a virtually flat performance (a decline of 0.6%) when compared to the same period 2015. Devaluation of local currencies had a negative effect on market developments.

2.2.8 Rest of the World

Sales in these countries amounted to EUR 35.5 million (US$ 39.6 million) in the first nine months of 2016, an increase of 3.8% in EUR terms (3.9% in US$ terms) when compared to the base period.

2.3 New product launches

In line with the strategic aim of renewing the product portfolio in all markets Richter introduced the following new products either in the third quarter 2016 or in the period between the end of the reporting period and the publication of this quarterly report:

Country	Product	Active pharmaceutical ingredient	Therapeutic area
Romania	Beatil	amlodipine+perindopril	Cardiovascular, anti-hypertensive
Bulgaria	Lisvy®*	gestodene + EE**	Women's Healthcare, contraceptive (patch)
	Lenzetto®*	estradiol	Hormone replacement therapy (spray)
Belgium	Lenzetto®*	estradiol	Hormone replacement therapy (spray)
Russia	Memantin-Richter	memantine	CNS, Alzheimer's disease

Notes: * Licensed-in product
** Ethynil estradiol

2.4 Women's Healthcare

In recognition of the strategic importance to the Company of this therapeutic area a brief presentation of the Women's Healthcare (WH) franchise is presented below. This therapeutic area includes the following product groups and therapeutic indications: oral contraceptives (OC) and contraceptive patch, emergency contraceptives (EC), contraceptive devices (CD); menopausal care, pregnancy care and obstetrics, gynaecological infections and other gynaecological conditions. Please refer to Appendix 2 on pages 32-33 for a comprehensive list of major products belonging to this therapeutic field.

2.4.1 Women's Healthcare sales by region

	HUFm				EURm			
	2016	2015	Change		2016	2015	Change	
	9 months to September			%	9 months to September			%
Hungary	3,902	3,974	-72	-1.8	12.5	12.9	-0.4	-3.1
EU *	43,288	41,185	2,103	5.1	138.6	133.4	5.2	3.9
Poland	2,446	2,801	-355	-12.7	7.8	9.1	-1.3	-14.3
Romania	1,650	1,589	61	3.8	5.3	5.1	0.2	3.9
EU 10	5,335	5,588	-253	-4.5	17.1	18.1	-1.0	-5.5
EU 15	33,857	31,207	2,650	8.5	108.4	101.1	7.3	7.2
CIS	20,379	21,981	-1,602	-7.3	65.3	71.2	-5.9	-8.3
Russia	16,432	17,320	-888	-5.1	52.6	56.1	-3.5	-6.2
Ukraine	1,383	1,487	-104	-7.0	4.5	4.8	-0.3	-6.3
Other CIS	2,564	3,174	-610	-19.2	8.2	10.3	-2.1	-20.4
USA	8,877	10,000	-1,123	-11.2	28.4	32.4	-4.0	-12.3
China	5,381	4,109	1,272	31.0	17.3	13.3	4.0	30.1
Latin America	3,631	3,496	135	3.9	11.6	11.3	0.3	2.7
RoW	4,917	4,094	823	20.1	15.8	13.2	2.6	19.7
Total	90,375	88,839	1,536	1.7	289.5	287.7	1.8	0.6
Average exchange rate (EURHUF)					312.23	308.82	3.41	1.1

Note: * All Member States of the EU, except for Hungary.

2.4.2 Sales

Women's healthcare sales totalled EUR 289.5 million in the first three quarters 2016, an increase of EUR 1.8 million compared to the levels reported in the nine months to September 2015. Total turnover generated from Richter's range of own developed oral contraceptive portfolio amounted to EUR 169.7 million, EUR 11.9 million lower when compared to the same period of 2015, primarily due to the weakening EURRUB exchange rate combined with the increasing generic competition experienced in the USA.

Sales arising from the OC portfolio acquired in 2010 amounted to EUR 35.0 million, EUR 3.1 million below the base period figure. Esmya® reported total sales were EUR 48.1 million in the first three quarters 2016, compared to the EUR 34.1 million turnover recorded in the base period.

2.4.2.1 Hungary

In **Hungary** WH sales totalled HUF 3,902 million (EUR 12.5 million) in the first three quarters 2016, representing a decline of HUF 72 million or EUR 0.4 million when compared to the levels reported in the same period 2015. Esmya® was launched in Hungary in May 2012 and the product was granted 90% reimbursed status in February 2013, while for the intermittent use in the long term management of uterine fibroids of Esmya® it was granted in September 2015. Its turnover during the reported period amounted to HUF 683 million (EUR 2.2 million).

2.4.2.2 European Union

Women's Healthcare sales in the **European Union**, excluding Hungary, amounted to EUR 138.6 million in the nine months to September 2016, increasing by EUR 5.2 million when compared to the base period.

Sales of Esmya®, our original product, were EUR 40.1 million during the reported period, EUR 11.7 million above the base period sales levels.

Sales of WH products represented 52% of the turnover in this region during the first three quarters 2016.

WH sales in **Poland** decreased by PLN 3.5 million to PLN 34.2 million (EUR 7.8 million) in the first nine months of 2016 as a consequence of high levels of parallel import and an environment of sustained price erosion. Turnover in **Romania** increased marginally by RON 0.9 million and amounted to RON 23.7 million (EUR 5.3 million) during the reported period. In the **EU10** region WH sales totalled EUR 17.1 million in the first three quarters 2016, EUR 1.0 million below the levels recorded in the same period of the previous year. With respect to WH sales the EU10 countries altogether represented 12% of the Group's WH sales to the whole EU region.

In the member states of the **EU15** region WH sales amounted to EUR 108.4 million in the nine months to September 2016, showing an increase of EUR 7.3 million when compared to the levels recorded in the same period of the previous year. This region contributed 78% of total EU WH sales.

In **Germany** Richter Group reported women's healthcare sales of EUR 34.6 million, EUR 3.4 million lower than the levels reported in the first nine months of 2015. Due to a negative media campaign related to hormonal contraceptives in general by the end of the first three quarters 2016 the overall market of contraceptives contracted by 6% (measured in cycles) year-on-year. Notwithstanding the above, sales of Esmya® grew by EUR 2.9 million by the end of the nine months to September 2016 year-on-year.

In **Spain** the Group's turnover arising from WH products amounted to EUR 14.7 million, EUR 4.9 million higher than in the base period. The year-on-year increase was primarily due to higher sales levels of Esmya®.

In **Italy** Richter Group achieved women's healthcare sales of EUR 14.1 million in the reported period, EUR 2.1 million above the levels reported in the same period of 2015.

In **France** the Group's turnover arising from WH products amounted to EUR 13.0 million, EUR 0.5 million lower compared with the first three quarters of 2015.

In the **UK** the Group realised a WH turnover of EUR 12.9 million, EUR 1.5 million above that reported in the base period. Sales of Esmya® grew by EUR 1.5 million in the first three quarters of 2016.

In **Portugal** the Group achieved EUR 8.1 million sales of WH products, EUR 3.6 million above the turnover recorded in the first nine months to September 2015.

Sales of WH products represented 83% of the turnover in the EU15 region during the first three quarters of 2016, a creditable performance by the recently established sales force teams.

2.4.2.3 CIS

WH sales to the **CIS** in the nine months to September 2016 totalled EUR 65.3 million representing a decline of EUR 5.9 million from the sales levels achieved in the base period. In RUB terms sales to **Russia**, within the region, reached RUB 4,017.7 million, showing an increase of RUB 394.3 million. Currency devaluations and declining purchasing power experienced both in Ukraine and in the Other CIS republics negatively impacted Women's Healthcare turnover.

Turnover of WH products represented 25% of total CIS sales in the reported period.

2.4.2.4 USA

WH sales in the **USA** totalled US$ 31.7 million (EUR 28.4 million) in the first nine months of 2016, a decrease of US$ 4.4 million (EUR 4.0 million) when compared to the same period in the previous year. Revenues resulting from the oral contraceptive related profit sharing agreements declined substantially due to increased generic competition while proceeds from our emergency contraceptives further increased during the reported period.

Sales of WH products, including the profit sharing related to drospirenone, represented 79% of US sales.

2.4.2.5 China

Sales of WH totalled EUR 17.3 million in the first three quarters 2016, EUR 4.0 million higher than the levels achieved in the same period 2015.

2.4.2.6 Latin America

Sales of WH totalled US$ 13.0 million in the first nine months of 2016, US$ 0.4 million higher than in the base period 2015.

2.4.2.7 Rest of the World

WH sales in these countries amounted to EUR 15.8 million (US$ 17.6 million) in the nine months to September 2016, an increase of EUR 2.6 million, (US$ 2.8 million) when compared to the first three quarters of 2015.

2.4.3 Highlights of women's healthcare product portfolio

2.4.3.1 Treatment of uterine myomas – Esmya®

Esmya® reported total sales were EUR 48.1 million in the first nine months to September 2016, compared to the EUR 34.1 million turnover recorded in the same period of the previous year.

Following its launch in the first quarter 2016 in Ecuador, in the second quarter 2016 Esmya® was also launched in Colombia, Iceland, Mexico and Mongolia. Esmya® was granted marketing authorizations in the second quarter 2016 in the Dominican Republic and in Costa Rica while in the third quarter 2016 in Suriname.

Following its approval for the long term management of uterine fibroids, Esmya® was granted reimbursed status by the end of September 2016 in the following countries: Germany, Netherlands, Denmark, Sweden, Hungary, Estonia, Slovakia, Austria, Portugal, Slovenia, Spain, UK, Finland, Luxembourg, Ireland and Italy.

2.4.3.2 Innovative contraception – Lisvy®

In line with the strategic aim of widening the product portfolio Lisvy®, a transdermal contraceptive patch licensed-in from Bayer HealthCare was launched in Hungary, Germany, Austria, Czech Republic, Poland, Italy, Slovakia and Portugal during 2015. In the first quarter 2016 Lisvy® was introduced in all three Baltic states, Belgium, Luxembourg, France and Spain. Subsequently, in the second quarter the product was also launched in Romania, Finland, Netherlands and Switzerland while in the third quarter it also reached the Bulgarian market. Total turnover achieved by Lisvy® during the reported period amounted to EUR 4.2 million.

On 10 October 2016 Richter initiated the voluntary withdrawal of gestodene and ethynil estradiol containing transdermal contraceptive patch Lisvy®. The step was taken with immediate effect on all markets involved.

The decision followed a notification received from Bayer HealthCare, the licensor and supplier of Lisvy®, according to which certain stability tests carried out under specific conditions resulted in out-of specification results. Consequently Bayer commenced an investigation to determine the root cause of such non-specific responses. In this endeavour Richter closely co-operates with Bayer.

Richter's actions have been taken after consultation with the responsible national authorities, although, by this date Richter has not received reports of any adverse events associated with this issue.

The above decision to remove Lisvy® from the market reflects Richter's utmost commitment to patients' safety.

2.4.3.3 Treatment of post menopause symptoms – Lenzetto®

Lenzetto®, the estradiol spray for treating menopause symptoms, licensed in from Acrux, an Australian company, also received multiple marketing approvals in European territories during September 2015. By the end of September 2016, Lenzetto® was launched in the following countries: Poland, Czech Republic, Hungary, Croatia, Latvia, Lithuania, Romania, Slovakia, Germany, Bulgaria and Belgium. Turnover of Lenzetto® during the reported period amounted to EUR 0.4 million.

2.4.3.4 Fertility – Bemfola®

Focusing on the meaningful widening of our core Women's Healthcare portfolio Gedeon Richter acquired the global rights (except for the USA) of the innovative biosimilar product Bemfola®, addressing female fertility.

Bemfola®, a recombinant-human Follicle Stimulating Hormone (r-hFSH) was developed by Finox as a biosimilar to Gonal-f®, an established reference product. Bemfola® was the first biosimilar r-hFSH launched in Europe.

The integration of the companies belonging to Finox Holding into Richter Group commenced subsequent to the closing of the transaction (8 July 2016). The integration of Finox Group will be completed by the time of publication of the quarterly report for the 12 months to December 2016.

Hereby we provide information on the turnover recorded by Bemfola® in the third quarter 2016, an amount to be formally included into the consolidated annual sales of the Group subsequent to the completion of the consolidation procedure.

Sales of Bemfola® recorded in the third quarter 2016 amounted to EUR 7.3 million (US$ 8.2 million).

2.5 Central Nervous System – cariprazine

As a consequence of the marketing approval granted in September 2015 by the Food and Drug Administration to Richter's original compound, cariprazine co-developed with Allergan (earlier Forest / Actavis) the product was launched in the USA by Allergan under the brand name Vraylar™ in March 2016. The product was authorized for the indications of schizophrenia and bipolar mania with a number of post marketing studies to be performed by the owners of the licence in the coming years. In addition to the authorized indications the developing companies are seeking further therapeutic approvals, conducting Phase III clinical trials with cariprazine in the treatment of bipolar depression and as adjunctive therapy in major depression.

First sales were generated by Vraylar™ in the very last few days of March 2016. Under the terms of the agreement between Richter and Allergan, Richter sells the active ingredient on a cost plus basis and receives royalties on subsequent product sales. Settlements are to be made within 45 days following the end of each quarter.

Royalty income of US$ 3.4 million (EUR 3.1 million) related to the first half 2016 sales performance of cariprazine (Vraylar™) contributed to the sales levels achieved during the reported period.

In March 2016 the European Medicines Agency (EMA) accepted Richter's regulatory submission for cariprazine for the treatment of schizophrenia in adult patients. Its approval is expected in Q2 / Q3 2017.

In August 2016 Richter and Recordati announced the signing of an exclusive license agreement to commercialize cariprazine in Western Europe, Algeria, Tunisia and Turkey.

3. Pharmaceuticals – Operating profit and margin

Operating profit for the Group originated primarily from the Pharmaceuticals segment. Operating profit for this business segment amounted to HUF 45,231 million during the first three quarters 2016, a decline of 13.5% when compared to the same period in 2015. Operating margin decreased to 19.1% from the 22.1% realised in the same period 2015 mainly as a result of a decline experienced at gross profit level, higher sales and marketing expenses and certain one-off expenses which were partly offset by one-off reassessment-related income related to our Chinese stakeholding subsequent to the acquisition announced in January 2016 and lower R&D expenses. Following the acquisitions made in 2010 the amortisation of both Esmya and the acquired OC portfolio were incurred as cost items in the reported period and amounted to HUF 5,642 million.

4. Wholesale and retail sales report

	HUFm				EURm			
	2016	2015	Change		2016	2015	Change	
	9 months to September			%	9 months to September			%
Hungary	88	104	-16	-15.4	0.3	0.3	0.0	0.0
EU *	40,584	33,335	7,249	21.7	129.9	107.9	22.0	20.4
Poland	-	-	-	-	-	-	-	-
Romania	40,584	33,335	7,249	21.7	129.9	107.9	22.0	20.4
EU 10	-	-	-	-	-	-	-	-
EU 15	-	-	-	-	-	-	-	-
CIS	9,622	9,705	-83	-0.9	30.8	31.5	-0.7	-2.2
Russia	-	-	-	-	-	-	-	-
Ukraine	-	-	-	-	-	-	-	-
Other CIS	9,622	9,705	-83	-0.9	30.8	31.5	-0.7	-2.2
USA	-	-	-	-	-	-	-	-
China	-	-	-	-	-	-	-	-
Latin America	3,014	2,960	54	1.8	9.7	9.6	0.1	1.0
RoW	-	-	-	-	-	-	-	-
Total	53,308	46,104	7,204	15.6	170.7	149.3	21.4	14.3
Average exchange rate (EURHUF)					312.23	308.82	3.41	1.1

Note: * All Member States of the EU, except for Hungary.

The principal aim of the Wholesale and Retail companies is to support the sales levels of our products on the Group's selected traditional markets.

Sales amounted to EUR 170.7 million in the first nine months 2016, a 14.3% increase compared to the same period of the previous year.

Our Romanian subsidiaries realised 76% of the turnover in the Wholesale and Retail segment (RON 583.2 million), with the remainder primarily being invoiced by our subsidiaries in the CIS region. The sales increase in Romania was 21.9% in RON terms (20.4% in EUR terms) in the first three quarters 2016. A slow reduction in payment delays continued on the Romanian pharma market during the reported period, yet excessive delays continue to prevail in the pharma sector.

5. Wholesale and retail – Operating profit and margin

The combined amount of operating profit from subsidiaries and the stakeholding proportional amount of income from associates and joint ventures operating in the Wholesale and retail segment totalled HUF 2,232 million during the reported period.

The consolidated operating profit of subsidiaries belonging to this segment was HUF 519 million, when compared to an operating profit of HUF 609 million realised in the base period.

Disclosures

I, the undersigned declare, that Gedeon Richter Plc. takes full responsibility, that the interim management report published today, which contains the Group's nine months to September 2016 results is prepared in accordance with the applicable accounting standards and according to the best of our knowledge. The report above provides a true and fair view of the financial position of Gedeon Richter Plc., comprises the subsidiaries included in the consolidation, contains an explanation of material events and transactions that have taken place during the reported year and their impact on the financial position of Gedeon Richter Plc. and its subsidiaries included in the consolidation.

Budapest, 3 November 2016

Erik Bogsch
Managing Director

The financial statements in this report cover the activities of Gedeon Richter Group ('The Group' or 'Richter Group') and Gedeon Richter Plc. ('The Company' or 'Richter'). These interim condensed financial statements are prepared in accordance with IAS 34 Interim Financial reporting. EUR and US$ amounts have been converted from HUF at average exchange rates for indicative purposes only. Financial statements for the twelve months to December 2015 are audited. Financial statements for the nine months period ended 30 September 2016 and 30 September 2015 are unaudited. The Company has adopted the same accounting policies during the preparation of this report as for the preparation of the most recent annual financial report.

Appendix 1

Products and active ingredients

The following products are referred to in this report:

Product	Active pharmaceutical ingredients	Therapeutic area
Aertal* / Aflamil */ Aflamin* / Airtal* / Biofenac*	aceclofenac	Non-steroid anti-inflammatory
Avonex*	interferon beta-1a	Central nervous system, multiple sclerosis
Beatil	amlodipine + perindopril	Cardiovascular, antihypertensive
Bemfola®	follitropin alfa	Women's Healthcare, fertility
Cavinton	vinpocetine	CNS, nootropic
Duamild	tamsulosine + finasteride	Urology, benign prostate hypertrophy
Escapelle / Plan B One Step	levonorgestrel	Women's Healthcare, emergency contraception
Esmya®	ulipristal acetate	Women's Healthcare, uterine myoma
Fasconal	acetylsalicylic acid + paracetamol+caffeine + codeine	Analgesic
Grofibrat, Grofibrat S	fenofibrat	Cardiovascular, lipid-lowering
Groprinosin	inosine pranobex	Antiviral
Kalmopyrin	acetylsalicylic acid	CNS, analgesic
Lenzetto®*	estradiol	Hormone replacement therapy (spray)
Lisvy®*	gestodene + EE**	Women's Healthcare, contraceptive (patch)
Lunaldin*/Dolforin*	fentanyl	Oncology, opioid analgesic
Memantin-Richter	memantine	CNS, Alzheimer's disease
Mertenil	rosuvastatin	Cardiovascular, cholesterol-lowering
Mydeton / Mydocalm	tolperisone	Muscle relaxant
Ossica	ibandronate	Oncology / Women's Healthcare, Osteoporosis
Suprax*	cefixime	Antibiotic
Vidotin Komb	perindopril + indapamid	Cardiovascular, antihypertensive
Verospiron	spironolactone	Cardiovascular, diuretic
Vidonorm	amlodipine + perindopril	Cardiovascular, antihypertensive
Vraylar™	cariprazine	CNS, antipsychotic

Notes: * Licensed-in
** Ethynil estradiol

Appendix 2

Women's healthcare products and active ingredients

Brand name	Active ingredients	Product type
Oral contraceptives (OC)		
Volina / Midiana / Aranka / Maitalon 30	DRP+30mcg EE	Fourth generation
Symicia / Daylette / Daylla / Volina Mite / Rezia / Maitalon 20 / Darylia / Dimia / Liladros / Arankelle	DRP+20mcg EE	Fourth generation
Regulon / Desorelle / Desmin 30	DSG+30mcg EE	Third generation
Novynette / Desmin 20 / Femina	DSG+20mcg EE	Third generation
Azalia / Lactinette	DSG	Third generation
Lindynette 20 / Karissa	GST+20mcg EE	Third generation
Lindynette 30	GST+30mcg EE	Third generation
Milligest / Tristin / Perlean	GST+30/40mcg EE	Third generation
Rigevidon / Microfemin	LVG+30mcg EE	Second generation
Tri-Regol	LVG+30/40mcg EE	Second generation
Belara / Chariva / Lybella / Balanca / Belarina / Evefem	CLM+30mcg EE	
Neo-Eunomin	BCLM+50mcg EE	
Eve 20	norethisterone+20mcg EE	First generation
Siluette / Mistral / Mistra / Sibilla	dienogest + 30 mcg EE	Fourth generation
Emergency contraceptives (EC)		
Postinor / Rigesoft / Levonelle-2 / Plan B	LVG (2x)	
Escapelle / Levonelle One-Step / Plan B One Step	LVG (1x)	
Other contraceptive methods (CM)		
Goldlily / Silverlily	Au+Cu, Ag+Cu	IUD
Levosert*	levonorgestrel	IUD
Lisvy®*	gestodene + EE	patch

Continued on the following page

Note: * Licensed-in

Abbreviations used:

LVG:	Levonorgestrel
EE:	Ethinyl estradiol
CLM:	Chlormadinone
DRP:	Drospirenone
GST:	Gestodene
DSG:	Desogestrel
BCLM:	Biphasic-chlormadinone

Continued from previous page:

Brand name	Active ingredients	Product type
Menopausal care		
Tulita / Minivel	norethisterone+estradiol	Hormone replacement therapy
Triaklim	norethisterone+estradiol	Hormone replacement therapy
Pausogest	norethisterone+estradiol	Hormone replacement therapy
Goldar*	tibolone	Hormone replacement therapy
Estrimax	estradiol	Hormone replacement therapy
Lenzetto®*	estradiol	Hormone replacement therapy (spray)
Ossica	ibandronate	Osteoporosis
Sedron / Ostalon / Siranin / Beenos	alendronate	Osteoporosis
Calci-Sedron-D / Ostalon Calci D	alendronate+Ca, vitamine D	Osteoporosis
Pregnancy care and Obstetrics		
Gravida*	vitamins	Pregnancy care
Oxytocin	oxytocine	Labour induction (injection)
Bromocriptin	bromocriptin mesilate	Prolactin inhibitor
Fertility		
Bemfola®	follitropin alfa	Fertility treatment
Gynaecological infections		
Mycosyst	fluconazole	Antifungal
Gyno Femidazol	miconazole nitrate	Antifungal
Gynofort / Gynazol*	butoconazole nitrate	Antifungal (cream)
Klion D	metronidazole+miconazole	Antifungal
Other Gynaecological conditions		
Esmya®	ulipristal acetate	Uterine myoma
Norcolut	norethisterone	Premenstruation syndrome, mastodynia, dysfunctional uterine bleeding, endometriosis
Loritan*		Medical pad for the detection of potential leakage of the amniotic liquid
Levosert*	levonorgestrel	Menorrhagia
Bulk Products		Oral contraception

Note: * Licensed-in

Abbreviations used:

LVG:	Levonorgestrel	DRP:	Drospirenone
EE:	Ethinyl estradiol	GST:	Gestodene
CLM:	Chlormadinone	DSG:	Desogestrel
		BCLM:	Biphasic-chlormadinone